Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
November 9, 2015
Revance Therapeutics Releases Third Quarter 2015 Results
November 9, 2015
Revance Therapeutics Announces Closing of Public Offering of Common Stock
November 4, 2015
Revance Therapeutics to Present at Credit Suisse 24th Annual Healthcare Conference
November 4, 2015
Revance Therapeutics to Release Third Quarter 2015 Financial Results Monday, November 9, 2015
November 4, 2015
Revance Therapeutics Announces Pricing of Public Offering of Common Stock
November 2, 2015
Revance Therapeutics Announces Proposed Public Offering of Common Stock
October 29, 2015
Revance Reports Positive 6-Month Duration in BELMONT Study
September 29, 2015
Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A for Injection to Treat Cervical Dystonia
September 28, 2015
Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Lateral Canthal Lines
September 9, 2015
Revance Therapeutics Initiates Phase 2 Clinical Trial of Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
Displaying 221 - 230 of 280